According to the data of , as of the press time of China Securities Journal on February 15, 58 of the 107 listed companies of medical devices in Shanghai and Shenzhen had disclosed the performance forecast of 2021. Among them, the performance of 41 companies is expected, accounting for more than 70%; The performance of 19 companies is expected to more than double.
industry insiders said that with the promotion of the new medical reform, policies such as unified consumables coding, centralized procurement of consumables and DRG / Dip medical insurance payment have reconstructed the product pattern of medical device manufacturers. Companies that actively promote technological innovation and seek opportunities to go to sea are expected to open up market space.
covid-19 testing company’s outstanding performance
The data show that among the 41 companies whose performance is expected to be happy, the performance of covid-19 testing companies is particularly bright. Beijing Hotgen Biotech Co.Ltd(688068) , Andon Health Co.Ltd(002432) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) are expected to more than double their performance.
In terms of covid-19 antigen detection, the performance forecast disclosed on the evening of Andon Health Co.Ltd(002432) January 20 shows that the company’s net profit attributable to shareholders of listed companies is expected to be RMB 900 million-1.2 billion in 2021, with a year-on-year increase of 271.40% – 395.19%; The net profit deducted from non profits was 850 million yuan to 1.15 billion yuan, with a year-on-year increase of 243.46% – 364.68%. For the reason for the substantial increase in performance, the company said that during the reporting period, the company’s New Coronavirus antigen self testing OTC kit product sales in the United States market sales increased significantly.
In terms of covid-19 nucleic acid detection, the performance forecast disclosed by Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) shows that the net profit attributable to shareholders of listed companies is expected to be 1.3-1.5 billion yuan in 2021, with a year-on-year increase of 177.23% – 219.88%; The net profit attributable to shareholders of listed companies was RMB 1.3 billion to RMB 1.5 billion, with a year-on-year increase of 185.66% – 229.61%. During the reporting period, the company added more than 1500 customers of molecular diagnostic medical institutions in China, and the sales of covid-19 nucleic acid detection reagent increased significantly.
The 2020 China in vitro diagnostic industry report released by the 8th China in vitro diagnostic industry development conference shows that the development trend in the next five years will be that the amount of routine testing will be reduced in at least two years (2020-2021), the income of nucleic acid testing related to covid-19 will increase significantly, the amount of antibody testing will fluctuate, and the demand for rapid antigen testing will increase, Covid-19 testing business may last until 2024 and promote the rapid development of the global IVD market.
strengthen innovation and R & D
In the performance forecast of 2021, many medical device companies said that innovative products have become the “engine” of rapid performance growth.
Shanghai Microport Endovascular Medtech (Group) Co.Ltd(688016) it is estimated that the net profit of the company will increase by 40% – 50% year-on-year in 2021. The company said that during the reporting period, the sales of the company’s innovative products, such as castor branch aortic covered stent and delivery system, Minos abdominal aortic covered stent and delivery system, reewarm PTX drug balloon dilation catheter, etc., continued to grow rapidly. The above products further consolidated and improved the company’s competitiveness in the aortic and peripheral vascular intervention market. At the same time, with the continuous expansion of the company’s innovative products in the international market, the overseas business income has also increased rapidly.
Eyebright Medical Technology(Beijing) Co.Ltd(688050) it is estimated that the company’s net profit in 2021 will increase by 65.70% – 86.42% year-on-year. The company said that the growth of net profit in the reporting period was mainly due to the rapid growth of sales of the company’s core products intraocular lens and corneal shaping lens and the increase of operating revenue. Among them, the sales volume of “pronomin” and other series of intraocular lenses is expected to increase by more than 40% compared with the same period of last year, and the sales volume of “pronomin pupil” corneal plastic lens is expected to increase by more than 110% compared with the same period of last year.
Kaiyuan Securities said that the DRG / Dip policy has no payment restrictions on treatment outside the hospital, which will be conducive to the large amount of postoperative auxiliary consumables; Innovative products can be declared with special payment by local government departments, or there will be great prospects.
On January 26, the national development and Reform Commission issued a document proposing to relax the market access restrictions of medicine and medical devices in Shenzhen. It is allowed to accept the medical device registration inspection report issued by the third-party inspection institution recognized by CNCA and the State Food and drug administration. Support the promotion of real-world data application in the full life cycle clinical evaluation of local drugs and medical devices in Shenzhen (including pre-market approval and registration of new drugs and devices, modification of approved drug device instructions, post-market safety research and active monitoring), focusing on clinical evaluation in the fields of clinical urgent need, rare disease treatment, AI medical algorithm, precision medicine, traditional Chinese medicine and so on, Further accelerate the listing process of new products, and timely discover and control the use risks of listed products.
After the policy was announced, the reporter of China Securities Journal noticed that a number of products of Sonoscape Medical Corp(300633) located in Shenzhen were registered and approved one after another. On February 11, Sonoscape Medical Corp(300633) said in response to investors’ questions that the accelerated registration of the company’s endoscopic products has a certain relationship with the State Food and Drug Administration’s adjustment of the classification of some medical devices since the end of 2020. The management category of some endoscopic products has been reduced from “III” to “II”, shortening the registration cycle. At the same time, the endoscopic products developed by the company are of good quality, and the registration process such as clinical trials is relatively smooth, so the registration progress is accelerated.
